17 active not recruiting, 13 completed, 12 recruiting, 4 not yet recruiting. 52 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 52 | Active not recruiting 17, Completed 13, Recruiting 12, Not yet recruiting 4, Unknown 4, Terminated 1, Withdrawn 1 |
| Phase 2 | 6 | Active not recruiting 3, Recruiting 2, Unknown 1 |
Follow Watchful Waiting: new trials by email Literature Review of Watchful Waiting trials Research Report on Watchful Waiting
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection - Lung Non-Small Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 336 | 2027-03-02 | 2026-10-29 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| Comparing Radiation After Surgery to Observation After Surgery in Patients With Clinical Low-Risk, Molecular High-Risk Meningioma, and Evaluating Observation After Surgery in Patients With Clinical and Molecular Low-Risk Meningioma Patient Observation, Magnetic Resonance Imaging, Biospecimen Collection - Grade 1 Meningioma, Grade 2 Meningioma | Phase 3 | Not yet recruiting | NRG Oncology | 464 | 2027-01-28 | 2026-08-25 |
| Adjuvant Trial in Pancreatic Neuroendocrine Tumors Adjuvant chemotherapy with Capecitabine-Temozolomide, Active surveillance - Pancreatic Neuroendocrine Tumors (pNET), Pancreatic Neuroendocrine Tumors | Phase 3 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 300 | 2026-09-01 | 2026-05-15 |
| Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness Pre-screening Phase, Screenig Phase, Randomization - Soil-Transmitted Helminths | Phase 3 | Recruiting | Insud Pharma | 20000 | 2025-09-01 | 2025-09-15 |
| NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment Active Surveillance, Control arm - Definitive bladder treatment - Muscle-Invasive Bladder Carcinoma | Phase 2 / Phase 3 | Recruiting | Peter Black | 688 | 2025-07-28 | 2025-07-30 |
| Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial Best Practice, Biospecimen Collection, Bone Metastases Treatment - Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm | Phase 3 | Active not recruiting | NRG Oncology | 280 | 2025-05-07 | 2026-08-17 |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) Bone Scan, Carboplatin, Computed Tomography - Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor | Phase 3 | Recruiting | Children's Oncology Group | 1656 | 2025-04-15 | 2026-08-25 |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial Biospecimen Collection, Computed Tomography, Durvalumab - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 306 | 2025-04-01 | 2026-10-19 |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma Biospecimen Collection, Bone Scan, Computed Tomography - Pleuropulmonary Blastoma | Phase 3 | Recruiting | Children's Oncology Group | 110 | 2025-03-21 | 2026-08-25 |
| Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion Sintilimab (9 cycles), Sintilimab (18 cycles), Active surveillance - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Tongji Hospital | 360 | 2024-06-01 | 2024-04-30 |
| Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Zanubrutinib, Rituximab, Patient Observation - Mantle Cell Lymphoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 421 | 2023-10-20 | 2026-10-02 |
| Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer Encorafenib, Cetuximab, Biospecimen Collection - Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma | Phase 2 / Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 1 | 2023-08-16 | 2026-07-02 |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab Pembrolizumab, Patient Observation, Biopsy - Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1295 | 2023-06-14 | 2026-08-05 |
| CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease CoQ10, Placebo, HB-HIIT - End Stage Renal Disease | Phase 3 | Recruiting | Vanderbilt University Medical Center | 156 | 2023-06-01 | 2026-01-02 |
| Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung Atezolizumab, Biospecimen Collection, Carboplatin - Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 189 | 2022-06-28 | 2026-10-29 |
| Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol - Metastatic Colon Cancer, Stage III Colon Cancer | Phase 3 | Active not recruiting | Massachusetts General Hospital | 400 | 2020-04-16 | 2026-09-09 |
| Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery Capecitabine, Fluorouracil, Leucovorin - Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8 | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 635 | 2019-12-16 | 2025-05-07 |
| Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma esophagectomy, chemoradiation, active surveillance - Esophageal Cancer | Phase 3 | Recruiting | Shanghai Chest Hospital | 176 | 2019-09-01 | 2019-10-22 |
| Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 636 | 2019-08-16 | 2026-10-26 |
Showing 20 of 52. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (5) · Colonic Neoplasms (4) · Anus Neoplasms (3) · Bile Duct Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Renal Cell (2) · Gallbladder Neoplasms (2) · HIV Infections (2) · Leukemia, Erythroblastic, Acute (2) · Leukemia, Megakaryoblastic, Acute (2) · Leukemia, Monocytic, Acute (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Acute (2) · Liver Neoplasms (2)
National Cancer Institute (NCI) (13) · Children's Oncology Group (7) · NRG Oncology (5) · Alliance for Clinical Trials in Oncology (3) · AIDS Malignancy Consortium (2) · ECOG-ACRIN Cancer Research Group (2) · Gustave Roussy, Cancer Campus, Grand Paris (2) · SWOG Cancer Research Network (2) · GOG Foundation (1) · Gynecologic Oncology Group (1) · Insud Pharma (1) · Jeroen Bosch Ziekenhuis (1) · Massachusetts General Hospital (1) · NICHD Neonatal Research Network (1) · Obstetrix Medical Group (1)
United States (37) · Canada (19) · Puerto Rico (12) · Australia (9) · France (5) · New Zealand (5) · Saudi Arabia (4) · China (3) · United Kingdom (3) · Finland (2) · Guam (2) · Israel (2) · Japan (2) · Netherlands (2) · Norway (2)
Alberto S. Pappo, MD (1) · Alejandro Krolewiecki, MD (1) · Amy A Smith (1) · Andrea B Apolo (1) · Anne Steiner, MD MPH (1) · Aparna Parikh, MD (1) · Atif Akdas, MD (1) · Baback Roshanravan, MD/MPH (1) · Bryan J. Donnelly, MD, FRCSC, MSC (1) · Cecile Le Pechoux, MD (1) · Christos Coutifaris, MD PhD (1) · Clive Stubbs (1) · David B Zhen (1) · David Gerber (1) · David Goldstein, MD (1)
PMID 16921051, PMID 20522709, PMID 20823433, PMID 21569373, PMID 22782416, PMID 23550669, PMID 25087673, PMID 26720308, PMID 28391003, PMID 29068800, PMID 29376112, PMID 30060087, PMID 30954717, PMID 31375516, PMID 31483448, PMID 31652094, PMID 31786124, PMID 32611448, PMID 33526329, PMID 33548339, PMID 33594934, PMID 34342619, PMID 34623899, PMID 34919827, PMID 35416975, PMID 35704479, PMID 35759733, PMID 36184192, PMID 36566574, PMID 36610886, PMID 38661512, PMID 38757485, PMID 38942046, PMID 39282902, PMID 39938471, PMID 40029972, PMID 41364689, PMID 41386267, PMID 41693026, PMID 41825136, PMID 42335416, PMID 42567733, PMID 42641639, PMID 42949119
U10CA180820 (7), U10CA180886 (6), U10CA180868 (5), U10CA098543 (4), U10CA021115 (3), U10CA180821 (3), U10CA180888 (3), U01CA121947 (2), U10CA027469 (2), U10CA031946 (2), U10CA180830 (2), U24CA196172 (2), 2025 (1), U10CA013539 (1), U10CA021661 (1)